Format

Send to

Choose Destination
Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):367-72. doi: 10.1016/j.clml.2011.06.005.

CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia.

Author information

1
Research Service, Veterans Affairs New York Harbor Healthcare System, New York, NY 10010, USA.

Abstract

INTRODUCTION:

Chronic lymphocytic leukemia (CLL) is a B-cell disorder, but it is also associated with abnormalities in T-lymphocyte function. In this study we examine changes in T-lymphocyte CD39 and CD73 expression in patients with CLL.

METHODS:

Blood samples were drawn from 34 patients with CLL and 31 controls. The cells were stained for CD3, CD4, CD8, CD19, CD39, and CD73 and analyzed by flow cytometry.

RESULTS:

Overall, patients with CLL had a higher percentage of CD39(+) T lymphocytes than did controls. The percentage of cells expressing CD39 was higher in both CD4(+) cells and CD8(+) cells. Higher CD3/CD39 expression was associated with a later disease stage. No correlations between T-lymphocyte CD39 levels and CD38 or Zap-70 expression were observed. In contrast, the percentage of T lymphocytes and B lymphocytes that expressed CD73 was decreased in patients with CLL. Average B-lymphocyte CD73 expression was decreased in CLL because the majority of CLL clones were CD73. However a minority of CLL clones were CD73(+), and patients with CD73(+) clones tended to have earlier stage disease.

CONCLUSION:

T-lymphocyte CD39 and CD73 expression may be useful prognostic markers in patients with CLL. Expression of CD73 on the malignant cell population in CLL may be a marker of better prognosis.

PMID:
21816376
PMCID:
PMC3590911
DOI:
10.1016/j.clml.2011.06.005
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center